Possible mechanisms of interaction between statins and vitamin D

QJM: An International Journal of Medicine

Volumn 105, Issue 5, 2012, Pages 487-491

  Bhattacharyya, S ^a   Bhattacharyya, K ^b   Maitra, A ^c  

^a Aultman Health Foundation   (United States)

^b INDIANA STATE UNIVERSITY   (United States)

^c Renal Consultants Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CYCLOSPORIN; CYTOCHROME P450 3A4; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; VITAMIN D;

DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HYDROXYLATION; DRUG INHIBITION; DRUG METABOLISM; DRUG STRUCTURE; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HUMAN; MYALGIA; NOTE; PRIORITY JOURNAL; VITAMIN D DEFICIENCY;

EID: 84859940521     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcs001     Document Type: Note

References (39)

1. Harper CR, Jacobson TA. Evidence-based management of statin myopathy. Curr Atheroscler Rep 2010; 12:322-30.
2. Goldstein MR, Mascitelli L, Pezzetta F. Statin therapy, muscle function and vitamin D. QJM 2009; 102:890-1.
3. Lee P, Greenfield JR, Campbell LV. Vitamin D insufficiency- a novel mechanism of statin-induced myalgia? Clin Endocrinol 2009; 71:154-5.
4. Bell DS. Resolution of statin-induced myalgias by correcting vitamin D deficiency. South Med J 2010; 103:690-2.
5. Ahmed W, Khan N, Glueck CJ, Pandey S, Wang P, Goldenberg N, et al. Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res 2009; 153:11-6.
6. Duell PB, Connor WE. Abstract 3701: vitamin D deficiency is associated with myalgias in hyperlipidemic subjects taking statins. Circulation 2008; 118:S 470.
7. Gupta A, Thompson PD. The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis 2011; 215:9-23.
8. Pérez-Castrillón JL, Abad Manteca L, Vega G, Del Pino Montes J, de Luis D, Duenas Laita A. Vitamin D levels and lipid response to atorvastatin. Int J Endocrinol 2010; 2010:320721.
9. Schwartz JB. Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence. Clin Pharmacol Ther 2009; 85:198-203.
10. Thummel KE, Brimer C, Yasuda K, Thottassery J, Senn T, Lin Y, et al. Transcriptional control of intestinal cytochrome P4503A by 1-alpha,25-dihydroxy vitamin D3. Mol Pharmacol 2001; 6:1399-406.
11. Drocourt L, Ourlin J-C, Pascussi J-M, Maurel P, Vilarem M-J. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J Biol Chem 2002; 277:25125-132.
12. Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Lown KS, Watkins PB. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1-alpha,25-dihydroxyvitamin D3. Mol Pharmacol 1997; 51:741-54.
13. Defay R, Astruc ME, Roussillon S, Descamps B, Crastes de Paulet A. DNA synthesis and 3-hydroxy-3-methylglutarylCoA reductase activity in PHA- stimulated human lymphocytes: a comparative study of the inhibitory effects of some oxyterols with special reference to side chain hydroxylated derivatives. Biochem Biophys Res Commun 1982; 106:362-72.
14. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmac-kinet 1997; 32:403-25.
15. Lea AP, McTavish D. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidemias. Drugs 1997; 53:828-47.
16. Mauro VF. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet 1993; 24:195-202.
17. Herman RJ. Drug interactions and the statins. CMAJ 1999; 161:1281-6.
18. Yashui Y, Suzuki R, Miyamoto S, Tsukamoto J, Sugie S, Kohno H, et al. Lipophilic statin, pitavastatin, suppresses inflammation associated with mouse colon carcinogenesis. Int J Cancer 2007; 121:2331-9.
19. Roche V. Antihyperlipidemic Statins: A self-contained, clinically relevant Medicinal Chemistry Lesson. Am J Pharm Educ 2005; 69. Article 77.
20. Beaird SL. HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles. J Am Pharm Assoc 2000; 40:637-44.
21. Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackarth I, et al. Comparison of cytochrome P450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 1999; 27:173-9.
22. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63:332-41.
23. Product Insert. Kowa Pharmaceuticals America, 2011 - LIV - RA - 0035, P-8. http://www.kowapharma.com/documents/LIVALO_PI_CURRENT.pdf.
24. Lea AP, McTavish D. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidemias. Drugs 1997; 53:828-47.
25. Victoria F, Roche. Antihyperlipidemic Statins: A Self-Contained, Clinically Relevant Medicinal Chemistry Lesson. Am J Pharm Educ 2005; 69. Article 77.
26. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol 2003; 55:94-9.
27. Meier C, Stey C, Brack T, Maggiorini M, Risti B, Krahenbuhl S. Rhabdomyolysis in patients treated with simvastatin/ ciclosporin: role of the hepatic P450 enzyme. Schweiz Med Wochenschr 1995; 125:27-8.
28. Barclay P, O'Connell P. Clarithromycin drug interactions complicating cyclosporine and simvastatin therapy [abstract]. Austral J Hosp Pharm 1996; 26:180.
29. Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med 1995; 333:664-5.
30. Horn M. Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals [letter]. Arch Dermatol 1996; 132:1254.
31. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264:71-5.
32. Tal A, Rajeshawari M, Isley W. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. South Med J 1997; 90:546-7.
33. Pilz S, Dobnig H, Fischer JE, Wellnitz B, Seelhort U, Boehm BO, et al. Low Vitamin D levels predict stroke in patients referred to coronary angiography. Stroke 2008; 39:2611-3.
34. Grimes DS. Statins and vitamin D. Cardiovasc Drugs Ther 2009; 23:261-2.
35. Ertugrul DT, Yavuz B, Cil H, Ata N, Akin KO, Kucukazman M, et al. STATIN-D Study: comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxyvitamin D. Cardiovasc Ther 2011; 29:146-52.
36. Pérez-Castrillón JL, Vega G, Abad L, Sanz A, Chaves J, Hernandez G, et al. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol 2007; 99:903-5.
37. Rejnmark L, Vestergaard P, Heickendorff L, Mosekilde L. Simvastatin does not affect vitamin D status, but low vitamin D levels are associated with dyslipidemia; results from a randomized controlled trial. Int J Endocrin 2010; 2010:957174.
38. Yavuz B, Ertugrul DT, Cil H, Ata N, Akin KO, Alcin AA, et al. Increased Levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after Rosuvastatin. Cardiovasc Drugs Ther 2009; 23:295-9.
39. Goldstein MR, Mascitelli L, Pezzetta F. Rosuvastatin and vitamin D: might there be hypovitaminosis D on JUPITER? Int J Cardiol 2010; 145:556-7.